AXA Posts 9% Net Profit Rise, Maintains 2026 Targets

French insurer AXA reported first-half net profit of €4.17 billion, up 9% at constant currency, and reaffirmed full-year targets, including upper-end underlying earnings growth and a 14%–16% return on equity.

AXA's First-Half Earnings: Growth Across Life & Health and P&C

AXA delivered a robust set of first-half numbers, with net profit climbing 9% at constant currency to €4.17 billion ($4.81 billion). The increase was driven by a 5% rise in gross written premiums and other revenue, which reached €66.29 billion.

The Life & Health segment was the standout performer, recording an 8% comparable increase in gross written premiums to €31.16 billion. Meanwhile, the Property & Casualty (P&C) business posted a more modest 3% rise, contributing €35.07 billion.

Following the results, AXA reiterated its financial targets for 2026. The insurer expects underlying earnings growth to land at the upper end of its 6%–8% targeted range and maintains an underlying return on equity of between 14% and 16% for the 2024–2026 period.

Why AXA's Life & Health Business Leads the Way

Life & Health: The Outperformer

The 8% premium growth in Life & Health suggests that AXA is benefiting from strong demand for protection and health solutions across its core markets. While no segment-specific drivers were detailed, the pace comfortably outran the group average and likely reflects both pricing power and volume gains in an environment where customers are increasingly prioritizing long-term savings and health coverage.

P&C: Steady but Slower

P&C’s 3% increase is respectable but indicates a more competitive landscape or a deliberate underwriting discipline that caps top-line expansion. AXA did not break out P&C combined ratios or claims trends, but the fact that the division still contributes the largest share of revenue (€35.07 billion) shows its central role in the group’s earnings engine.

Confidence in 2026 Targets

Reaffirming the full-year outlook—and specifically aiming for the upper end of the 6%–8% earnings growth range—signals that management sees limited downside risk to the remainder of 2026. This confidence likely rests on continued momentum in Life & Health, a stable claims environment in P&C, and supportive financial markets for the investment portfolio. Still, the absence of detail means that any external shock (e.g., extreme weather events or a sharp turn in interest rates) could test that conviction as the year progresses.

What Investors Should Watch as AXA Targets Upper-End Growth

Earnings growth target: With AXA guiding to the upper end of 6%–8%, investors will scrutinize the third-quarter and full-year results for any softening in premium trends or unexpected claims activity that could derail that outcome.
Life & Health momentum: The segment is the group's growth engine; any slowdown in its 8% premium growth trajectory would likely raise questions about AXA's ability to hit the raised ROE target, which sits at the top of the European peer group.
Capital management: If earnings continue to over-deliver, AXA may have additional scope for share buybacks or special dividends—strategies the insurer has used before. The full-year results will be the next clear signal on capital deployment plans.

Risk & Opportunity Assessment

Commercial Risk	Low	Earnings and premiums are rising, and AXA has explicitly backed its targets, indicating limited immediate commercial headwinds.
Competitive Risk	Medium	P&C growth of only 3% may reflect competitive pricing pressure in key markets; if competitors gain share through aggressive rates, AXA's top-line expansion could slow further.
Regulatory Risk	Low	No specific regulatory challenges were mentioned; as a large European insurer, AXA faces standard Solvency II requirements but no unique imminent risk.
Reputation Risk	Low	No negative events disclosed; strong earnings and guidance confirmation typically support a stable reputation.
Technology Disruption	Low	The announcement contains no discussion of insurtech threats or digital transformation challenges that would materially alter AXA's near-term outlook.
Commercial Opportunity	Medium	The 8% growth in Life & Health suggests a clear opportunity to capture increasing demand for protection products, particularly if demographic trends and health awareness continue to drive premium volumes.